Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Debt: 2018-2025

  • China SXT Pharmaceuticals' Total Debt fell 98.64% to $102,601 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year decrease of 8.19%. This contributed to the annual value of $798,448 for FY2025, which is 30.85% up from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Total Debt of $102,601 as of Q3 2025, which was down 87.15% from $798,448 recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Total Debt ranged from a high of $12.2 million in Q1 2021 and a low of $11,404 during Q1 2022.
  • Over the past 3 years, China SXT Pharmaceuticals' median Total Debt value was $556,794 (recorded in 2023), while the average stood at $1.6 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Total Debt skyrocketed by 13,819.33% in 2021, and later crashed by 99.91% in 2022.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Debt (Quarterly) stood at $2.1 million in 2021, then tumbled by 43.04% to $1.2 million in 2022, then tumbled by 58.26% to $503,405 in 2023, then surged by 1,399.16% to $7.5 million in 2024, then plummeted by 98.64% to $102,601 in 2025.
  • Its Total Debt stands at $102,601 for Q3 2025, versus $798,448 for Q1 2025 and $7.5 million for Q3 2024.